Literature DB >> 9130644

Cytotoxicity and weak CD40 ligand expression of CD8+ type 2 cytotoxic T cells restricts their potential B cell helper activity.

S Sad1, L Krishnan, R C Bleackley, D Kägi, H Hengartner, T R Mosmann.   

Abstract

Naive CD8+ T cells differentiate into distinct cytokine-secreting subsets: T helper (Th)1-like cytotoxic T cells (Tc1) and Th2-like Tc2. Although Th2 cells provide strong B cell help, we show that Tc2 cells secreting the same cytokines provide only modest B cell help for IgM production, and only when large numbers of B cells were stimulated with small numbers of Tc2 cells. Lack of effective B cell help by Tc2 cells was attributable partly to their cytotoxicity towards B cells. Both Tc1 and Tc2 cells killed small resting B cells mainly by a perforin-dependent mechanism. In contrast to normal Tc2 cells, perforin-deficient Tc2 cells failed to kill small resting B cells and induced IgM and IgG1 production, although their B cell help was significantly lower than that mediated by Th2 cells. This may be partly attributable to the ability of Tc2 but not Th2 cells to kill activated B cells even in the absence of perforin. Plate-bound anti-CD3 antibodies inhibited Tc2 killing of B cells and induced substantial immunoglobulin production. Additionally, Tc1 and Tc2 cells failed to express CD40 ligand (CD40L), whereas Th1 and Th2 cells expressed high levels of CD40L. Stimulation of Tc1 and Tc2 cells with plate-bound anti-CD3 antibodies for extended periods resulted in low-level expression of CD40L. Proliferation of small resting B cells correlated with immunoglobulin production: proliferation was promoted strongly by Th1 and Th2, weakly by normal Tc1 and Tc2, and moderately by perforin-deficient Tc1 and Tc2 cells. Thus, Tc2 cells may not contribute significantly to cognate B cell help during normal responses.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9130644     DOI: 10.1002/eji.1830270417

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

Review 1.  Reflections on CD8 T-cell activation and memory.

Authors:  David Masopust; Rafi Ahmed
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

2.  CD40L expression permits CD8+ T cells to execute immunologic helper functions.

Authors:  Marco Frentsch; Regina Stark; Nadine Matzmohr; Sarah Meier; Sibel Durlanik; Axel R Schulz; Ulrik Stervbo; Karsten Jürchott; Friedemann Gebhardt; Guido Heine; Morgan A Reuter; Michael R Betts; Dirk Busch; Andreas Thiel
Journal:  Blood       Date:  2013-05-29       Impact factor: 22.113

3.  Abnormal CD40 ligand (CD154) expression in human immunodeficiency virus-infected children.

Authors:  M R O'Gorman; B DuChateau; M Paniagua; J Hunt; N Bensen; R Yogev
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

4.  CD40 ligand-mediated interactions are involved in the generation of memory CD8(+) cytotoxic T lymphocytes (CTL) but are not required for the maintenance of CTL memory following virus infection.

Authors:  P Borrow; D F Tough; D Eto; A Tishon; I S Grewal; J Sprent; R A Flavell; M B Oldstone
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

Review 5.  Programmed cell death: the influence of CD40, CD95 (Fas or Apo-I) and their ligands.

Authors:  N Laytragoon-Lewin
Journal:  Med Oncol       Date:  1998-04       Impact factor: 3.064

6.  Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells.

Authors:  Wendy K Roberts; Ilana J Deluca; Ashby Thomas; John Fak; Travis Williams; Noreen Buckley; Athanasios G Dousmanis; Jerome B Posner; Robert B Darnell
Journal:  J Clin Invest       Date:  2009-06-08       Impact factor: 14.808

7.  Meningococcal PorB induces a robust and diverse antigen specific T cell response as a vaccine adjuvant.

Authors:  Munir Mosaheb; Lee M Wetzler
Journal:  Vaccine       Date:  2018-10-28       Impact factor: 3.641

8.  A critical role for CD40-CD40 ligand interactions in amplification of the mucosal CD8 T cell response.

Authors:  L Lefrançois; S Olson; D Masopust
Journal:  J Exp Med       Date:  1999-11-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.